In Vitro Evaluation of Combination Antifungal Activity against Fusarium Species Isolated from Ocular Tissues of Keratomycosis Patients

American Journal of Ophthalmology

Volumn 146, Issue 5, 2008, Pages

  Li, Li ^a   Wang, Zhiqun ^a   Li, Ran ^a   Luo, Shiyun ^a   Sun, Xuguang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; NATAMYCIN; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; FUNGUS ISOLATION; FUSARIUM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KERATOMYCOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 54449096131     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.06.008     Document Type: Article

References (22)

1. Ritterband D.C., Seedor J.A., Shah M.K., Koplin R.S., and McCormick S.A. Fungal keratitis at the New York Eye and Ear Infirmary. Cornea 25 (2006) 264-267
2. Gopinathan U., Garg P., Fernandes M., Sharma S., Athmanathan S., and Rao G.N. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea 21 (2002) 555-559
3. Xuguang S., Zhixin W., Zhiqun W., et al. Ocular fungal isolates and antifungal susceptibility in Northern China. Am J Ophthalmol 143 (2007) 131-133
4. Rosa Jr. R.H., Miller D., and Alfonso E.C. The changing spectrum of fungal keratitis in South Florida. Ophthalmology 101 (1994) 1005-1013
5. Lalitha P., Shapiro B.L., Srinivasan M., et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol 125 (2007) 789-793
6. Therese K.L., Bagyalakshmi R., Madhavan H.N., and Deepa P. In-vitro susceptibility testing by agar dilution method to determine the minimum inhibitory concentrations of amphotericin B, fluconazole, and ketoconazole against ocular fungal isolates. Indian J Med Microbiol 24 (2006) 273-279
7. Dursun D., Fernandez V., Miller D., and Alfonso E.C. Advanced fusarium keratitis progressing to endophthalmitis. Cornea 22 (2003) 300-303
8. Baddley J.W., and Pappas P.G. Antifungal combination therapy: clinical potential. Drugs 65 (2005) 1461-1480
9. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium Forming Filamentous Fungi. Proposed Standard. NCCLS Document M38-P (2002), National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania
10. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of filamentous Fungi. Approved Standard. NCCLS Document M38-A (2002), National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania
11. Gupta A.K., and Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 149 (2003) 296-305
12. Vitale R.G., Afeltra J., and Dannaoui E. Antifungal combinations. Methods in molecular medicine. In: Ernst E.J., and Rogers P.D. (Eds). Antifungal Agents: Methods and Protocols (2005), Humana Press Inc, Totowa, New Jersey 143-152
13. Iyer S.A., Tuli S.S., and Wagoner R.C. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens 32 (2006) 267-271
14. Ganegoda N., and Rao S.K. Antifungal therapy for keratomycoses. Expert Opin Pharmacother 5 (2004) 865-874
15. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., and SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46 (2002) 1032-1037
16. Lass-Flörl C., Kofler G., Kropshofer G., et al. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 42 (1998) 497-502
17. Ortoneda M., Capilla J., Javier Pastor F., Pujol I., and Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 48 (2004) 69-71
18. Rothe A., Seibold M., Hoppe T., et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 83 (2004) 394-397
19. Ghannoum M.A., and Rice L.B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12 (1999) 501-517
20. Sugar A.M. Use of amphotericin B with azole antifungal drugs: what are we doing?. Antimicrob Agents Chemother 39 (1995) 1907-1912
21. Ghannoum M.A., Spellberg B.J., Ibrahim A.S., et al. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother 38 (1994) 2029-2033
22. Te Welscher Y.M., Ten Napel H.H., Balagué M.M., et al. Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem 283 (2008) 6393-6401